Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects

References

• Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, et al. 2007. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry. 46(45):13019–13030.
   PubMed Web of Science ®Google Scholar
• Anuurad E, Semrad A, Berglund L. 2009. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord. 7(5):401–410.
   PubMed Web of Science ®Google Scholar
• Avcikurt AS, Sinan S, Kockar F. 2015. Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity. J Enzyme Inhib Med Chem. 30(2):245–249.
   PubMed Web of Science ®Google Scholar
• Basit A, Neradugomma NK, Wolford C, Fan PW, Murray B, Takahashi RH, Khojasteh SC, Smith BJ, Heyward S, Totah RA, et al. 2020. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 17(11):4114–4124.
   PubMed Web of Science ®Google Scholar
• Cooke CE, Lee HY, Xing S. 2014. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. J Manag Care Pharm. 20(1):86–92.
   PubMed Web of Science ®Google Scholar
• Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto AD, Santos G, Krivine A, Delaugerre C, et al. 2013. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade. J Antimicrob Chemother. 68(11):2626–2631. eng.
   PubMed Web of Science ®Google Scholar
• Fu J, Sadgrove M, Marson L, Jay M. 2016. Biotransformation capacity of carboxylesterase in skin and keratinocytes for the penta-ethyl ester prodrug of DTPA. Drug Metab Dispos. 44(8):1313–1318. eng.
   PubMed Web of Science ®Google Scholar
• Hatfield MJ, Potter PM. 2011. Carboxylesterase inhibitors. Expert Opin Ther Pat. 21(8):1159–1171. eng.
   PubMed Web of Science ®Google Scholar
• Hossain MA, Tran T, Chen T, Mikus G, Greenblatt DJ. 2017. Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. J Pharm Pharmacol. 69(12):1786–1793.
   PubMed Web of Science ®Google Scholar
• Huang HY, Daar ES, Sax PE, Young B, Cook P, Benson P, Cohen C, Scribner A, Hu H. 2008. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection. HIV Med. 9(5):285–293.
   PubMed Web of Science ®Google Scholar
• Inoue NR, Hall A, Lai WG, Williams ET. 2013. Reversible inhibition of human carboxylesterases by acyl glucuronides. Drug Metab Dispos. 41(4):698–703.
   PubMed Web of Science ®Google Scholar
• Jewell C, Ackermann C, Payne NA, Fate G, Voorman R, Williams FM. 2007. Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver. Drug Metab Dispos. 35(11):2015–2022.
   PubMed Web of Science ®Google Scholar
• Jiang J, Chen X, Zhong D. 2018. Predominant contributions of carboxylesterase 1 and 2 in hydrolysis of anordrin in humans. Xenobiotica. 48(5):533–540.
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Fukami T, Yoshida T, Nakajima M. 2016. Arylacetamide deacetylase is responsible for activation of Prasugrel in human and dog. Drug Metab Dispos. 44(3):409–416.
   PubMed Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. 2005. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol. 70(11):1673–1684.
   PubMed Web of Science ®Google Scholar
• Margolis AM, Heverling H, Pham PA, Stolbach A. 2014. A review of the toxicity of HIV medications. J Med Toxicol. 10(1):26–39.
   PubMedGoogle Scholar
• Marzolini C, Gibbons S, Khoo S, Back D. 2016. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 71(7):1755–1758.
   PubMed Web of Science ®Google Scholar
• Meanwell NA, Krystal MR, Nowicka-Sans B, Langley DR, Conlon DA, Eastgate MD, Grasela DM, Timmins P, Wang T, Kadow JF. 2018. Inhibitors of HIV-1 attachment: the discovery and development of Temsavir and its Prodrug Fostemsavir. J Med Chem. 61(1):62–80.
   PubMed Web of Science ®Google Scholar
• Mizoi K, Takahashi M, Sakai S, Ogihara T, Haba M, Hosokawa M. 2020. Structure-activity relationship of atorvastatin derivatives for metabolic activation by hydrolases. Xenobiotica. 50(3):261–269.
   PubMed Web of Science ®Google Scholar
• Nettles R, Chien C, Elefant E, Wang X, Chung E, Zhu L, Zhang D, Wu Y, Persson A, Grasela D. 2011. Single and multiple dose pharmacokinetics and safety in non-HIV-infected healthy subjects dosed with BMS-663068, an oral HIV attachment inhibitor. 12th International Workshop on Clinical Pharmacology of HIV Therapy.
   Google Scholar
• Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 338(13):853–860. eng.
   PubMed Web of Science ®Google Scholar
• Pancera M, Lai YT, Bylund T, Druz A, Narpala S, O'Dell S, Schön A, Bailer RT, Chuang GY, Geng H, et al. 2017. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 13(10):1115–1122.
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, Weissig H, Aban A, Chun D, Tanner S, Kozarich JW. 2007. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry. 46(2):350–358.
   PubMed Web of Science ®Google Scholar
• Reese M, Sakatis M, Ambroso J, Harrell A, Yang E, Chen L, Taylor M, Baines I, Zhu L, Ayrton A, et al. 2011. An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem Biol Interact. 192(1–2):60–64.
   PubMed Web of Science ®Google Scholar
• Reust CE. 2011. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 83(12):1443–1451.
   PubMed Web of Science ®Google Scholar
• RUKOBIA (fostemsavir) [package insert]. 2020. ViiV HealthCare; [accessed 2022 August 11]. www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf.
   Google Scholar
• Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. 2017. Cobicistat versus Ritonavir: similar pharmacokinetic enhancers but some important differences. Ann Pharmacother. 51(11):1008–1022. eng.
   PubMed Web of Science ®Google Scholar
• Umehara K, Zollinger M, Kigondu E, Witschi M, Juif C, Huth F, Schiller H, Chibale K, Camenisch G. 2016. Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors. Xenobiotica. 46(10):862–867.
   PubMed Web of Science ®Google Scholar
• UNAIDS. 2016. Global Aids Update 2016.
   Google Scholar
• Watkins ME, Wring S, Randolph R, Park S, Powell K, Lutz L, Nowakowski M, Ramabhadran R, Domanico PL. 2017. Development of a Novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate. J Pharm Sci. 106(3):906–919.
   PubMed Web of Science ®Google Scholar
• Ziessman HA. 2019. Sincalide: a review of clinical utility, proper infusion methodology, and alternative cholecystogogues. J Nucl Med Technol. 47(3):210–212.
   PubMed Web of Science ®Google Scholar